Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR.70/IL15-transduced CB-derived NK Cells for Advanced RCC, Mesothelioma, and Osteosarcoma
NCT05703854Phase 2Suspended
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2023
- Primary completion
- Sep 2027
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CAR.70/IL15-transduced CB-NK cells in renal cell carcinoma (RCC), mesothelioma and osteosarcoma (OS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started Mar 2023; status: suspended.
02
Drugs
CAR.70/IL15-transduced CB-NK cells
03
Conditions
renal cell carcinoma (RCC)mesotheliomaosteosarcoma (OS)
Beyond the preview
Go deeper on NCT05703854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05703854.